From: Tocilizumab for relapsing and remitting giant cell arteritis: a case series
Patient | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age | 80 | 80 | 76 | 76 | 79 | 82 | 75 | 72 | 63 | 61 | 72 | 75 | 59 | 76 | 70 | 63 | |
Sex | M | M | M | F | F | F | F | F | F | F | F | F | M | F | M | F | |
Ethnicity | Other | Arabic | White | Other | White | White | Other | White | Other | White | White | White | White | White | White | White | |
Duration of GCA disease (months) before TOC | 5 | 11 | 6 | 25 | 71 | 61 | 1 | 12 | 30 | 7 | 22 | 148 | 52 | 9 | 24 | 24 | |
Medication | Steroid dose at start of TOC (mg) | 40 | 20 | 40 | 20 | 25 | 10 | 60 | 40 | 5 | 30 | 10 | 30 | 20 | IM 10-weekly | 20 | 20 |
Most recent steroid dose (mg) and date | 0, Aug 2019 | 5, Feb 2021 | 7, Feb 2021 | 0, Feb 2020 | 10, Jan 2021 | 2, Nov 2020 | 3, Jan 2021 | 10, Feb 2019 | 5, Dec 2020 | 10, May 2020 | 0, May 2020 | 5, May 2021 | 10, May 2021 | – | 7, March 2021 | 10, May 2021 | |
Months on TOC | 13 | 18 | 22 | 25 | 12 | 12 | 31 | 12 | 17 | 1 | 17 | 13 | 8 | 15 | 1 | 12 | |
Concurrent DMARD dose at TOC start | MTX 15 mg qw | – | – | MTX 15 mg qw | – | – | – | – | – | MTX 25mg qw | – | Lef 20 mg od | – | – | MTX 25 mg qw | ||
Blood results | ESR at presentation | 28 | 49 | 15 | 32 | 55 | 13 | 51 | 60 | 110 | 10 | 63 | 40 | – | 8 | 38 | – |
ESR before start of TOC | 2 | 29 | 4 | 32 | 8.7 | 5 | 51 | 48 | 10 | 12 | 18 | 16 | – | 2 | 22 | 13 | |
ESR after start of TOC | 2 | 4 | 2 | 20 | 2 | 2 | 42 | 23 | 6 | 2 | 5 | 2 | – | 2 | 2 | – | |
CRP at presentation | 403 | 176 | 3.5 | 43 | 105 | 10.9 | 37 | 128 | 26 | 20 | 49 | 30 | – | 10 | 63 | – | |
CRP before start of TOC | 7.8 | 9.1 | < 1.0 | 5.8 | 3.3 | 5.1 | 37 | 18 | < 4.0 | 8 | 7.2 | 4.5 | – | < 4.0 | 35 | 20 | |
CRP after start of TOC | < 1.0 | 0.7 | < 1.0 | 3.3 | 1.8 | 1.9 | 14 | 3.3 | < 4.0 | < 1.0 | < 4.0 | 1 | – | < 4.0 | 1.4 | – | |
Temporal artery biopsy | Neg | Pos | Pos | Neg | Pos | Inconclusive | Inconclusive | Pos | Neg | Neg | Neg-late | Not done | Neg | Not done | Neg | Pos | |
Comorbidities | PMR, IHD, PVD | RA | PMR, HypoT | PMR | PMR, HTN | RA | CVA, vasculitis | Takayasu’s arteritis | HypoT | PMR | PMR | PMR |